{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-008448","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.455063+00:00","generated_at":"2026-06-08T04:31:26.023692+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs","bullets":["Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.","Cash and equivalents $10.8M as of Sep 30, 2023, roughly flat vs year-end 2022.","Post-quarter: Walloon funding approved for ~$6M; expects $13M milestone payments from Heska.","FDA agreed to traditional 510(k) pathway for Nu.Q NETs test following Q-Sub process.","Launched Nu.Q Vet Test in UK/Ireland via NationWide Laboratories and Veterinary Pathology Group."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-008448","json":"https://secwatch.observer/filing/0001477932-23-008448.json","markdown":"https://secwatch.observer/filing/0001477932-23-008448.md","text":"https://secwatch.observer/filing/0001477932-23-008448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/0001477932-23-008448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:31:26.023692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a0a100e4518e22bbf020783168c0fc32153dc32e","claim":"VOLITIONRX LTD reported the third quarter ended September 30, 2023 results: revenue $531,000.","evidence_excerpt":"over the prior year period, reflecting sales of the reference kits through our global, regional and local supply agreements. Additionally, total year-to-date revenue was $531,000, a 185% increase compared to the comparable period of 2022. We believe that these results demonstrate steady growth, but not yet the “ramp” in revenues that we anticipate. We","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/0001477932-23-008448-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$531,000"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}